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Abstract
With the political, social and financial drives for cancer research, many advances have been made in the treatment
of many different cancer types. For example, given the increase in awareness, early detection, and treatment of
breast and prostate cancers, we have seen substantial increases in survival rates. Unfortunately there are some
realms of cancer that have not seen these substantial advancements, largely due to their rapid progression and the
inability to specifically target therapy.
The hypothesis that cancers arise from a small population of cells, called cancer stem cells (CSCs), is gaining more
popularity amongst researchers. There are, however, still many skeptics who bring into question the validity of this
theory. Many skeptics believe that there is not a specific subset of cells that originate with these characteristics, but
that they develop certain features over time making them more resistant to conventional therapy. It is theorized
that many of the relapses occurring after remission are due to our inability to destroy the self-renewing CSCs. This
central idea, that CSCs are biologically different from all other cancer cells, has directed research towards the
development of therapy to target CSCs directly. The major dilemma in targeting therapy in myeloproliferative
disorders, malignancies of the central nervous system or malignancies in general, is the inability to target CSCs as
opposed to normal stem cells. However, with the recent advances in the identifications of unique molecular
signatures for CSCs along with ongoing clinical trials targeting CSCs, it is possible to use targeted nanotechnology-
based strategies in the management of different types of cancers.
Keywords: Cancer Stem Cell Cancer Stem Cell Like, Molecular Signature, Cell Surface Markers, Microenvironment,
Targeted Therapy, Chemoresistance, Cancer Recurrence, Signaling Pathways
Introduction
When discussing potential targets for the treatment of
cancer today, the conversation will generally lean
towards targeted therapy of cancer stem cells (CSCs).
With the identification of potential defining characteris-
tics for CSCs, there have also been more questions
raised as to which of these characteristics may make
better targets. For many years, research seemed to focus
on isolating CSCs by specific identifying markers but
the research has seemed to shift towards identifying the
way in which these stem cells behave that make them
different from bulk tumor cells. Limited efficacy has
been seen with the use of cell surface markers in clinical
trials; however, there have been recent advances that
target other aspects such as signaling pathways or
genetic alterations seen particularly in CSCs. The fol-
lowing is a review of what information is out there and
what seem to be the most promising paths on this jour-
ney to identifying therapeutic targets of self-renewing
CSC sub-populations.
Identifying Characteristic Cell Surface Markers
Identifying CSCs by their outer appearance or cell sur-
face markers has been focused on by many researchers.
The concept of identifying CSCs by these markers is a
rational one. The challenge in targeting CSCs is identify-
ing which cell surface markers are going to be the dis-
tinguishing factors that will make them a suitable target.
One of the biggest discoveries in the identification of
cell surface markers involved leukemic stem cells (LSCs).
The discovery of CD34+/CD38- as a cell surface marker
on AML leukemic cells gave the first indication that
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would allow for targeting of CSCs [1,2]. With this identi-
fication it was determined that only cells that were
located in the CD34+/CD38- population of progenitor
cells had the capacity to initiate leukemia in NOD-SCID
mice when compared with CD34- and CD34+/CD38+
cells [2]. Upon further investigation it was determined
that those cells that expressed CD34 on their cell surface
also strongly expressed BCRP, a member of the ABC
transporters, which play an important role in dug efflux.
It has also been found that BCRP is the key player in
drug efflux in AML leukemic cells as opposed to P-gP
which is common in many other biological systems [3].
Although identification of this subpopulation is an
important discovery in terms of narrowing the search for
a viable target, it only gives information that LSCs are
derived from a subpopulation of immature bone marrow
cells. It did also provide researchers with a definition of
CSCs for AML. It identified a separate population within
AML cells that were able to cause cancer transplantation
into NON-SCID mice. For this reason there has been a
movement in cancer research to target subpopulations
within the CD34+/CD38- subpopulation in order to
further target LSCs (Table 1).
Another cell surface marker widely used in the study
of AML treatment is CD33, given its extensive expres-
sion on LSCs. CD33 is an immunoglobulin that is
believed to aid in regulation of cellular differentiation
[4]. CD33 has been found to be expressed on 80-90%
of leukemic cells in those patients suffering from
AML. Not only has CD33 been widely used in research
but it has also made it as far as FDA approval [3,5].
Anti-CD33 antibodies have become an important
aspect of CSC targeted therapy. A therapy, called
Gemtuzumab ozogamacin (GO) or Mylotarg, approved
by the FDA in 2000, combines calicheamicin (a cyto-
toxic antibiotic) with an anti-CD33 antibody. Mylotarg
has been approved for use in CD33+ AML patients
who are 60 years of age or older, who are not candi-
dates for other cytotoxic chemotherapy but are experi-
encing 1
st relapse. Guidelines for the treatment of
elderly patients suffering from AML still indicate the
use of intensive chemotherapy as first line in those
who are in good enough health to receive it [6]. Those
who are candidates for treatment with intensive che-
motherapy, such as daunorubicin in combination with
cytarabine, generally are less than 70 years of age, have
aW B C< 1 0 0×1 0
9/l and no adverse cytogenic
abnormalities or MDR expression. These general char-
acteristics are reiterated in a study by the Southwest
Oncology Group that assessed cytogenic and multidrug
resistance subgroups in elderly patients who were
refractory to standard chemotherapy treatment [7].
A phase I trial, conducted by Sievers et al., first gave
insight into the use of Mylotarg in patients with refrac-
tory or relapsed AML [8]. This study investigated the
e f f e c t so fw h a ti sn o wM y l o t a r go n4 0r e l a p s e dA M L
patients, with a median age of 54. Disappearance of leu-
kemia, among the trial participants, was indicated by
absence of leukemic blast cells in the peripheral blood
with <5% leukemic blasts present in the bone marrow.
Further, complete remission was defined by disappear-
ance of disease plus an ANC > 1,500/ul and a platelet
count .100 × 10
3/ul, without transfusions. Results from
this trial showed that 8 of the 40 patients (20%) of those
treated with GO experienced complete remission [8].
Table 2 illustrates ongoing clinical trials targeting CSC
in different cancer types.
Table 1 Cancer Stem Cell molecular signatures in different cancer types: Potential for CSC targeting
Target Type Specific Target Cancer Type Use
Cell surface
markers
CD34+/CD38- Acute Myelogenous Leukemia Identification has allowed for characterization of LSCs. Too
broad to use as a target for chemotherapy but is very useful
in identification for further characterization.








PI3K/Akt/mTOR FDA approved therapy for renal cell
carcinoma. Evidence that may be effective in
other solid tumors.
Temsirolimus, Everolimus FDA approved for renal cell
carcinoma.
Hedgehog Evidence in basal cell carcinoma but has





Increase ROS within cells leading to apoptosis,
being investigated in many cancers including
CML.
Synergistic effect seen when imatinib and simvastatin in CML.
Microenvironment Mesenchymal
stem cells
Evidence in Glioma but being investigated in
many solid tumors.
Used in vivo as a target, also being investigated as a drug
delivery system.
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labeled, phase II, multicenter trials, performed in 2001,
the safety and efficacy of Mylotarg treatment in AML
patients experiencing first relapse, was determined [9].
There were 2 types of responses evaluated during this
study. A complete response was defined by leukemic
blasts absent from the peripheral blood, <5% blasts bone
marrow aspirate or biopsy, peripheral blood counts with
hemoglobin levels of 9 g/dL or greater, ANC ≥ 1,500/ul
and platelet count ≥ 100,00/ul and RBC transfusion
independence for 2 weeks and platelet transfusion inde-
pendence of at least 1 week. There was also a subset of
those evaluated who experienced complete response
with the exception of full recovery of platelet counts
before they required the next treatment(CRp)[ 9 ] .T h e
number of people that experienced these responses was
combined to determine an overall response rate for the
study. This study, composed of 142 CD33+ AML
patients with a median age of 61 years, showed that
there was an overall response rate of 30% with a median
time to response of 60 days. It was also indicated that
the median overall survival was 5.9 months [9]. The
final report for this study, published in 2005, indicated
similar results [10]. The final report showed that
among the 277 patients treated with GO, there was a
26% response rate with a median overall survival of
4.9 months.
According to a new phase III trial that studied the
effect of GO on AML patients who were in remission,
there was no increase in survival rates among those who
used GO when compared to no treatment post remission
[11]. Patients in this study were composed of those
patients who had experienced complete remission who
were then offered 3 cycles of GO or no further treatment.
The purpose of this study was to investigate whether
treatment with GO post remission may be instrumental
in preventing relapse among AML patients. This study
included 232 patients who were randomized to either the
treatment with GO group or the no treatment group
(113 patients in GO arm and 119 patients in no treat-
ment arm). Among these patients there were 2 types of
induction chemotherapy used in order to obtain the
complete remission. These treatments included induction
therapy with 45 mg/m
2 dose schedule of daunorubicin
(days 1, 2, 3) and cytarabine 200 mg/m
2 (days 1-7) or
induction therapy with daunorubicin 90 mg/m
2.A m o n g
the treatment and no further treatment arms, there was
no statistically significant difference in the amount of
patients who used either therapy [11]. As stated, this
study showed no statistically significant difference in sur-
vival rates between these 2 groups. This study also pro-
vided a more lucid adverse effect profile for Mylotarg.
Among the adverse effects of fever, sepsis and hepatic
and gastrointestinal toxicities, there was also a strong
indication of hematologic toxicity, commonly seen in the
form of cytopenias [11]. This might not seem all that sur-
prising as they are the all too familiar adverse effects
associated with the majority of chemotherapy; however,
this is evidence that the common concentration of CD33
on normal cells needs further investigation.
There may be many reasons why there was no statisti-
cally significant difference in survival rates seen among
those who were treated with GO and those who received
no treatment post remission. One reason may have been
that there was a decrease in the expression of CD33 on
CSCs but another reason may have been due to efflux
mechanisms associated with CSCs. A brief report on the
phase II trials mentioned previously [9,10] showed a
potential correlation between response to GO therapy
and P-gP activity [12]. This report evaluated all of the
patients who were treated with GO and compared the
responders (CR and CRp) to non-responders. Results
show that there may be an increase in P-gp activity and a
decrease in CD33 expression in those who did not
respond to GO therapy [12]. Further studies have been
done to determine what LSC characteristics are asso-
ciated with an increased sensitivity to GO. An in vitro
analysis of chemo-sensitivity of LSCs, performed by
Table 2 Update on clinical trials for CSC molecular targets
Target Drug Cancer Phase http://clinicaltrials.gov/ Sponsor
Identifier
Notch MK0752 Breast I NCT00106145 Merck
Pancreatic I, II NCT01098344 Cancer Research UK
RO4929097 Renal cell II NCT01141569 University Health Network, Toronto
PF-03084014 Leukemia I NCT00878189 Pfizer
Hedgehog GDC-0449 Solid tumors I NCT00968981 Genentech
Colorectal II NCT00636610 Genentech
PF04449913 Hematologic I NCT00953758 Pfizer
BMS833923 Basal cell I NCT00670189 Bristol-Myers Squibb
LDE225 Medulloblastoma I NCT00880308 Novartis
Modified from (Ref. [44]).
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expression, P-gp-negative status and low % leukemic
stem and progenitor cells and GO sensitivity [13].
One cell surface marker that seems to be gaining
popularity is C-type lectin-like molecule or CLL-1. CLL-
1 is a type II, transmembrane glycoprotein that has
become the subject of interest in the targeted treatment
of LSCs [14]. The identification of CLL-1+ cells within
the CD34+/CD38- subpopulation has lead to not only a
potential target for therapy but also as a marker in diag-
nosis and prognosis [15]. One of the hardest parts of
finding a cell surface marker as a target in the treatment
of LSCs is being able to identify one that is present in
all cases of that cancer but at the same time not present
on normal cells. For this reason, an in vitro study that
identified that CLL-1 is present on AML CD34+/CD38-
cells but is not present on normal bone marrow CD34
+/CD38- cells is an important find in terms of potential
targets for AML [15]. This study included leukemic cell
samples from 89 patients who underwent Fluorescence-
activated cell sorting (FACS) in order to obtain leukemic
cells that were CD34+/CD38-/CLL-1+. When taking
into consideration different types of AML based on the
French-American-British classification, it was deter-
mined that CLL-1+ was present on all classes of FAB
(M0-M6). From this study it was determined that the
expression of CLL-1 varies vastly between samples and
seems to have no correlation with the different FAB
classes. This in turn indicates that they have found no
significant correlation between expression of CLL-1 and
potential prognostic factors. It may be important to note
that normal bone marrow samples of CD34+/CD38+
progenitor cells were partly CLL-1+ as well [15]. This is
important because it means that care should be taken
before specifically targeting CLL-1 cells rather than tar-
geting these cells within a subpopulation. From this
study it was also determined that NOD/SCID mice
transfected with CD34+/CD38-/CLL-1+ cells were able
to produce AML blasts cells that were CLL-1+.
Although this does not indicate that CLL-1 is required
for transfection of AML because it was not compared to
CD34+CD38-/CLL-1- cells, it does offer a potential tar-
get in terms of CSCs. The potential as a target comes
from the fact that none of the CD34+/CD38- cells from
normal bone marrow expressed CLL-1 whereas all of
the AML CD34+/CD38- cells expressed CLL-1 in this
study. As indicated in a 2010 review article, expression
of CLL-1 has been detected on as high as 92% of AML
cases [4]. This can be truly important if identification of
a cell surface marker that can be targeted in all types of
AML is possible.
Given the heterogenic response to GO among AML
patients experiencing remission, further studies should
be done to determine what targets could be added to this
treatment to increase the response rates. Also further
research should be considered in finding an alternative
target such as CLL-1 given the fact that studies have
shown that chemotherapy resistant lines of AML, such as
K562, are CD33- [16]. With the adverse effect profile
noted in recent clinical studies, it is likely that CD33 may
be fairly extensive on normal humans stem cells (HSCs)
and for this reason should be re-evaluated as a potential
target [11]. Although CD33+ cells are predominantly
located within the CD34+CD38- subpopulation, their
presence may not be a defining characteristic of LSCs.
As mentioned previously, av i a b l et a r g e tf o rA M Li s
CLL-1 as a cell surface maker. There have been advances
in the identification and characterization of CLL-1 and
its relationship to AML. Given its almost exclusive
expression on AML blast cells and its expression seen in
all types of AML, it may be a viable target although there
is not much evidence as of yet to indicate if there are any
therapeutic uses in targeting AML CSCs. The study of
LSCs may benefit from combining anti-CLL-1 antibodies
with conventional AML chemotherapy such as daunoru-
bicin. It will only be with studies like these that current
implications of CLL-1 targeting in AML can be verified.
Different formulations for conventional chemotherapy
without specific targets have been attempted but indicate
no benefit over the conventional treatment. One such
study that indicates this is the comparison of daunorubi-
cin and liposomal daunorubicin in older patients experi-
encing complete remission of AML. This study resulted
in no statistically significant differences in toxicity or
response among the 2 different treatment groups. Results
of this study further indicate the need for therapies that
are targeted to more specific cells [17].
Targeting of Signaling Pathways
Another means of targeting CSCs has been by signaling
pathways that seem to be up-regulated or specific to the
functionality of stem cells. Just as a friend can be identified
by superficial characteristics, they can also be identified by
the way that they speak or the way that they behave. The
fact that many cancers can share the same up-regulation
of certain pathways also makes targeting of stem cell
signaling pathways a good option. Some of the pathway
targeting that seems to show some potential is the PI3K/
Akt and Hedgehog pathways.
The activation or up-regulation of this pathway has
been associated with activation of survival and prolifera-
tive mechanisms utilized by malignant cells [18]. The
entire PI3K/Akt/mTOR pathway is a long cascade of
phosphorylative reactions; however, there are a few very
important key players that have been studied as potential
targets due to their implications in tumorogenic activ-
ities. The play that is farthest upstream is Phosphatidyli-
nositol 3-kinase (PI3K) which is a heterodimeric lipid
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mTOR pathway. PI3Ks are divided into classes of I, II or
III and then further into subclasses. Class I PI3K works
to phsophorylate the 3’-OH group of inositol lipids of
which gives rise to, among many products, Akt [19].
Activating mutations in the gene encoding for p110
(PIK3CA), a catalytic subunit of Class IA PI3Ks, have
been found in many different types of human cancer
[20]. Akt2, one of three Akt isoforms, is a protein kinase
which, when activated, plays a critical role in tumor
metastasis and invasion.
Downstream of Akt is the mammalian target of rapa-
mycin (mTOR). mTOR is so named for its ability to be
inhibited by rapamycin, also known as sirolimus, which
is an immunosuppressant used to prevent renal trans-
plant rejection [21]. It is critical for the production of
mRNA that is vital for cancer cell growth [18]. mTOR is
an enzyme that functions as a protein kinase and is
involved in production of many products used for cell
proliferation, survival and angiogenesis, for example
VEGF [20]. mTOR can also be classified by different
complexes that can be formed including mTOR com-
plex 1 (mTORC1) and mTOR complex 2 (mTORC2),
both which play critical roles in cell survival [20]. Each
portion of the pathway is indicated in different functions
for enhancement of tumorogenic effects but overall,
activation of this pathway leads to decreased apoptosis
and autophagy and an increase in translation, cell
growth, ribosome biogenesis, metabolism and prolifera-
tion in cancer cells [20]. In a recent in vitro study per-
formed by Bleau et al., identified the PTEN/PI3K/Akt
pathway as playing a key role in characteristic features
of glioma side-population cells [22]. Side populations
have been identified as playing a key role in the identifi-
cation of CSCs. The discovery of side populations came
from staining of bone marrow cells with Hoechst 33342
vital dye and discovering that there was a small popula-
tion of cells that were not stained but also expressed
certain CSC surface markers previously identified
[23,24]. Side populations are believed to have an efflux
mechanism that allows the Hoechst dye to be expelled
from the cells. This efflux mechanism is also believed to
play a role in the multiple drug resistance effects asso-
ciated with CSCs. The side populations in the study
were identified using the same method of staining with
Hoechst dye and were then evaluated for a correlation
with the PTEN/PI3K/Akt pathway. This correlation was
determined when the amount of SP cells in PDGF-
induced glioma (a well-characterized form of glioma) of
PTEN intact mice was compared to the amount of side
population cells in PTEN-deficient mice. The loss of
PTEN resulted in a doubling in the amount of side
population cells. The PTEN-deficient cells contained
33.1% sp cells while the cell with PTEN intact exhibited
15.5% sp cells. This can confer that up-regulation of the
PI3K/Akt pathway can be implicated in the survival and
proliferation of CSCs. In order to determine the role of
this pathway on resistance the PTEN-depleted and
PTEN-intact cells were incubated with mitoxantrone
both before and after incubation with a PI3K inhibitor
(LY294002, 20ྒྷM). As suspected the PTEN-deleted cells
resulted in an increased resistance to mitoxantrone and
incubation with LY294002 resulted in a significant
decrease in both the PTEN-intact (3.6 ± 0.4%-fold) and
in the PTEN-deleted (3.0 ± 0.7%-fold) tumors. Of note,
when the side population cells were tested with mTOR
and Akt inhibitors, mTOR inhibition resulted in a lim-
ited effect on termination of side population cells while
Akt inhibitors resulted in complete inability of the
transporter to cause efflux of mitoxantrone [22]. Indica-
tions that the PI3K pathway is constitutively active in
30-40% of human cancers make it a good potential tar-
get that may yield benefits in the entire field of cancer
rather than a target that will show results in a very
specific cancer type [18].
Investigations into the PI3K/Akt/mTOR pathway have
also shown some potential for targeting CSCs [20,22,25].
Integrin linked kinase (ILK) is also involved in phos-
phorylation of Akt and is over-expressed in many malig-
nancies including AML blast cells [26]. One of the
hardest parts of targeting cancers is being able to target
cells when they are quiescent. Interestingly, there is an
over-expression of ILK during this phase which may
play a part in the survival of cells or prevention of apop-
tosis [26]. Based on this evidence, research was per-
formed to determine the effect of using an ILK inhibitor
along with chemotherapy to target active cells as well as
those that were quiescent. When a novel ILK inhibitor
(QLT0267) was administered in vitro to cultured AML
cells, with either Ara-C or Daunorubicin, there was in,
most cases, a synergistic or additive effect. In 2 out of
10 cases there was, however, an antagonistic effect [26].
One of the targets in this pathway with the most out-
comes is a class called rapamycin inhibitors. This class of
inhibitors works on the mammalian target of rapamycin
or mTOR portion of the pathway [27]. This pathway is
found farthest downstream in the PI3K/Akt/mTOR path-
way and seems to have the most evidence so far, showing
effectiveness in the treatment of renal cell carcinoma.
Although this has the most clinical evidence to date,
there are other indications, as mentioned previously, that
other parts of the pathways may have more benefit in tar-
geted cancer therapy [22,27]. Two rapamycin analogs,
temsirolimus and everolimus, have received FDA
approval for use in the treatment of renal cell carcinoma.
Rapamycin as well as theses rapamycin analogs do not
exhibit their effects by direct binding to the catalytic site
of mTORC1 but rather bind FK506 (mTORC1
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results in inhibition of signaling events further down-
stream [20]. There have also been many clinical trials
performed as well as many clinical trials in process that
investigate monotherapy or combination therapy with
both temsirolimus and everolimus in other types of can-
cers [28-30]. Results of these trials indicate some efficacy
in terms of increasing progression free survival rates,
however, results at the end of the studies were generally
still dismal overall. In the clinical trial comparing temsir-
olimus and an investigator’s choice therapy, there was a
statistically significant increase in survival rates in
patients suffering from refractory or relapsed mantle cell
lymphoma (MCL). Investigator’sc h o i c et h e r a p yw a sa
single dose of gemcitabine, fludarabine, chlorambucil,
cladribine, etoposide, cyclophosphamide, thalidomide,
vinblastine, alemtuzumab or lenalidomide. The median
progression free survival rates for high dose temsiroli-
mus, low dose temsirolimus and investigator’sc h o i c e
therapy were 4.8, 3.4 and 1.9 months respectively [28].
While these results are statistically significant, they do
not seem to do much for the overall clinical outcomes. In
a recent trial, the response to treatment with everolimus
10 mg in those suffering from Waldenstrom Macroglo-
bulinemia was studied. Waldenstrom Macroglobulinemia
is a B-cell lymphoproliferative disorder. Each cycle was
defined as 4 weeks at which time a CBC was performed
to evaluate ANC, platelet count and presence of grade 3
or 4 hematological toxicities. If patients had no sign of
toxicities they were continued on treatment with 10 mg
daily. If the patients experienced toxicities, treatment was
stopped until signs resolved at which time they were trea-
ted in a stepwise fashion up to 5 mg everolimus daily.
This clinical trial studying everolimus treatment, in
51 patients, showed no complete response, 42% with par-
tial remission and 28% with a minimal response. When
the article was published 14% of patients had died and
26% of patients had experienced disease progression [30].
Disease progression was defined as a 25% increase in
monoclonal protein from baseline. When comparing
toxicities seen between these 2 studies, it seems as
though there are some added toxicities associated with
treatment, more of which seemed to occur in temsiroli-
mus. There was however a much larger sample size being
investigated in treatment with temsirolimus. Upon treat-
ment with everolimus, 56% of patients experienced grade
3 or higher toxicities while patients treated with temsiro-
limus resulted in grade 3 or higher toxicities in 80-89% of
patients depending on dose [28,30].
Phosphatase and tensin homolog (PTEN) is a lipid and
protein phosphatase that is drawing much attention in
cancer given its tumor suppressing effects which have
been negated by genetic alterations [20,22,31]. PTEN
inhibits the phosphorylative effects of PI3K by
dephosphorylating phosphatidylinositol-3-triphosphate
which is a product of PI3K activity [32]. With these
genetic alterations, PTEN is inhibited and the PI3K
pathway is free to up-regulate resulting in increased cell
proliferation and decreased apoptosis. The above men-
tioned studies and review indicate that PTEN could be
another possible step to target in the PI3K pathway.
Another potential target that seems to show some effi-
cacy is the targeting of the Hedgehog (Hh) pathway [33].
The hedgehog pathway is characterized by a few key
players including the hedgehog ligand, the Patch
(PTCH) transmembrane receptor and the Smoothened
(SMO) transmembrane protein. Under normal circum-
stances, PTCH is an inhibitory cell-surface receptor that
acts a tumor-suppressor which acts by inhibiting
smoothened, which in turn inhibits further activations
of the hedgehog pathway [34].
Alterations and activation of the hedgehog signaling
have been shown to play a role in the survival of medul-
loblastoma, basal cell carcinoma, pancreatic adenocarci-
noma and small lung cell carcinoma [35]. Smoothened,
a transmembrane protein has been identified as central
to the activation of the Hh pathway [35]. A recent study
has shown that by genetically modifying mice to make
them devoid of the Smoothened allele there is no effect
on the survival or maintenance of normal hematopoietic
cells. After analyzing the effects on the mice, it was
determined that there was no difference in peripheral
cells counts and no effect even on repopulation of stem
cells after stress [35]. These finding can be very impor-
tant in that it identifies the Hedgehog as a target that
may result in a therapy with decreased side effects.
Although there is limited data available in terms of
clinical trials there are many that are in progress to
determine the use of hedgehog inhibitors in the treat-
ment of different cancer types. One novel Hh inhibitor,
GDC-0449, has been examined in an open label clinical
trial [33]. This study investigated the use of GDC-0449
in patients suffering from advanced basal cell carcinoma.
A total of 33 patients with advanced basal cell carci-
noma, 18 of which had metastatic carcinoma, were trea-
ted with GDC-0449. The overall response rate among
those with metastases was 50% while the 15 patients
with localized disease experienced a 60% response rate
[33]. Of note, 2 patients with advanced lesions on the
face and head showed a drastic decrease in the size of
the lesions. These results can indicate an improvement
in the overall quality of life in those experiencing such
deforming lesions.
Some new studies are coming forth that are exploring
the use of statins for additive treatment during che-
motherapy treatment. Statins or HMG-CoA reductase
inhibitors are believed to pl a yar o l ei nr e a c t i v eo x y g e n
species (ROS) activity by leading to increases in NO
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and hydroxyl radicals and are known to play important
roles in aging and apoptosis among other things.
Increases in ROS within the cells cause damage to DNA
and protein that at low levels can actually lead to differ-
ent types of cancers. However, high levels of ROS can
be damaging to cancer cells and cause apoptosis [36].
There are beliefs that CSCs utilize ways to avoid these
oxidative stresses to increase the rate of survival. One
theory is that they act as anaerobic bacteria do, by hav-
ing low production of mitochondrial oxidative phos-
phorylation. It is believed that during these hypoxic
conditions, there is a large production of ATP, which
researchers believe may be due, in part, to synthesis by
Acetyl-coA synthetase [36]. HMG-coA reductase pro-
duces mevalonate and other products that indicated in
the control of cellular functions like cell signaling and
cell cycle progression [37]. Researchers have indicated
that apoptosis induction by statin can occur by inhibit-
ing HMG-coA reductase but also by increased produc-
tion of Nitric oxide levels [36,37]. This increase in NO
activity may lead to an increase in apoptosis as shown
by increased survival among cells pre-treated with an
iNOS inhibitor prior to treatment with statins [37].
Many studies have been performed to analyze the use of
statins as an adjunct to chemotherapy but one in parti-
cular may offer insight to its potential use in the treat-
ment of leukemias. This study, performed by Chen et
al., showed the synergistic effect of imatinib and simvas-
tatin in the treatment of CML. This synergistic effect
was believed to be due to an increase in ROS levels
within the cancer cells leading to apoptosis, indicated by
the lack of synergy when a NAC, a ROS scavenger, was
added to the simvastatin and imatinib combination [38].
The use of statins for potential synergistic cytotoxic
effects is exciting given the ease of administration and
its relatively low side effect profile.
Another exciting target against survival mechanisms of
CSCs are the efflux mechanisms. The discovery of efflux
mechanisms associated with CSCs has primarily come
from the study of “side populations.” Side populations,
as described previously, are present in many types of
cancers and are associated with the CSC population.
One of the most common targets among these efflux
pumps is the P-Glycoprotein (P-gp) pump. A recent
study showed great targeting potential using anti-P-gp
functionalized oxidized single walled carbon nanotu-
bules (Ap-SWNTs) combined with doxorubicin and its
effect on AML K562R cells. K562R cells are shown to
be very resistant to chemotherapy and for this reason
were a good candidate for this study. From this study it
was determined that using Ap-SWNT loaded with dox-
orubicin extensively decreased cell viability when com-
pared to doxorubicin alone and with other targeting
mechanisms. This was an in vitro study performed in
culture so it may be beneficial to perform in vivo studies
in murine models [39].
Another recent study indicated that the use of cyclos-
porine may be a candidate for inhibition of P-gp and
may have advantages for concomitant use with che-
motherapy. This was demonstrated by comparing dau-
norubicin alone and daunorubicin plus cyclosporine in
the K562/ADM strain of AML. Results of this study
indicated that after 6 hours of incubation with daunoru-
bicin plus cyclosporine, the sensitivity of the K562/ADM
strain approached that of the daunorubicin sensitive
K562 strain of AML cells [40].
Overall, if research can reveal the mechanisms that are
used by LSCs to avoid apoptosis or increase survival
rates, new therapies can be derived that target these
mechanisms. Moving forward in the study of survival
mechanisms, there seems to be a great value in the
study of efflux mechanisms. As with many other cancer
treatments, the best result sw i l ll i k e l yb es e e nw h e n
combining cytotoxic drugs with targets for P-gp efflux
mechanisms.
Targeting the Microenvironment
Along with the increase in research targeting LSCs speci-
fically, there is also an increase in research that will target
their lifeline. One key area of research is determining the
effect of mesenchymal stem cells on CSCs. Studies have
indicated that the presence of mesenchymal stem cells
with LSCs leads to a reduction in proliferation and a
decrease in apoptosis. One study evaluated the prolifera-
tion of leukemic cells that were exposed to a serum
deprivation of starvation condition with or without
mesenchymal stem cells. There was a very large decrease
in the amount of cells produced in the plates that co-
cultured mesenchymal stem cells and K562 (leukemic
strain) cells [41]. This leads to the belief that mesenchy-
mal stem cells can help force cancerous stem cells into a
quiescent state making them less susceptible to conven-
tional cancer treatments that target actively proliferating
cancer cells. This decrease in apoptosis is believed to be
contributed to up-regulation of PI3K-Akt pathway [42].
Although mesenchymal stem cells have been identified
as a life-line for LSCs, recent studies have identified
them as potential drug delivery systems. Some therapies
that have been developed in the treatment of brain
tumors such as glioma, have shown effective therapy
when injected intra-tumorally. An example of such
treatment is the monoclonal Ab 806 which targets the
ΔEGFR, an epidermal growth factor shown to be up-
regulated in cancers such as glioma, breast and lung.
Treatment of mice with xenografted gliomas with mAb
806 had a decrease in tumor growth as well as a 61.5%
increase in median survival rates compared to those
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ent and resulted in relapse and increased growth of the
tumor. The theory behind this relapse was that the
treatment was not delivered throughout the tumor [43].
In order to target malignant diseases, there is a need for
systemically administered therapies to be able to home
in on their intended targets. Recent studies have showed
results in the treatment of glioma that may offer insight
into the treatment of malignant diseases. One such
study shows that human mesenchymal stem cells
(hMSC), genetically modified to secrete single-antibody
fragments that have specific high affinity binding for
EGFRvII (scFvEGFRvIII), can be identified in much
higher concentrations within the brain tumor cells than
other organs [41]. Although this study was developed to
elucidate treatment options for glioma, this could likely
be an optimal area of research for treatment of many
different cancers. If mesenchymal stem cells could be
modified to carry different targeted therapies, for exam-
ple sTRAIL, there may be an increase in the concentra-
tion delivered to LSCs present within the tumor.
Study of the role of the microenvironment in terms of
LSC survival is very important; however the focus
should be more on the communication between the
microenvironmentand the stem cells. Until we learn
more about the microenvironment’se f f e c to nr e g u l a r
HSCs, targeting of the communication or signaling
pathways between them should be considered.
Conclusions
The overall goal of cancer therapy is to target the cancer
cells only while leaving viable normal cells unscathed.
Some types of cancers can make this job seem impossi-
ble given the inability to distinguish. However, with cur-
rent evidence, the future of targeted CSC eradication
does not seem like such a daunting task. Although tar-
geting of CSCs by their specific cell surface markers
seems like a very logical approach to target therapy,
results seem to indicate that other targeting strategies
like signaling pathways or microenvironment may offer
better results. This is not to say that identification of
cell surface markers does not have its place in terms of
studying CSCs. If we can identify different populations
of cells that exhibit these cell surface markers and iden-
tify them as stem cells we can evaluate the effectiveness
of new targeting strategies on that population.
By targeting other characteristics of stem cells, such as
specific pathways they use or ways they manipulate their
environment for survival, benefit can be seen without
spending time on research to prove the hypothesis of
CSCs. If we can show now that there are cells that have
specific behaviors that decrease apoptosis or efflux
mechanisms that make them resistant, then we are one
step further in finding treatment to destroy them
regardless of whether they are CSCs or cells that have
obtained certain survival mechanisms through evolution.
Table 2 summarizes ongoing clinical trials targeting
CSC [44].
Increasing research is being aimed at targeting CSCs
as opposed to the conventional targeting of homologous
tumor cells. With increasing evidence, an intricate puz-
zle is being pieced together that is revealing an image
consistent with targeted CSC therapy using those
unique CSC probes in a nanotechnology-based targeted
delivery with cytotoxic agents of CSC and cancer cells.
In conclusion, targeting CSC, cancer cells, and its asso-
ciated micro-environment might provide novel strate-
gies in the management of cancer. However, there is a
critical need for more direct surrogate markers (imaging
of CSC reduction in the tumor microenvironment or
reduction of circulating CSC) to assess the direct impact
of those CSC targeted therapies in clinical trials listed in
Table 2.
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